AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.

Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.

The company had discovery programs that are either completed, in progress, or under contract with partners.

It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets.

The company was incorporated in 2012 and is headquartered in Vancouver, Canada.